Biotechnology News and Research RSS Feed - Biotechnology News and Research

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI). [More]
Paragon Bioservices receives CMO Leadership Awards for 2015

Paragon Bioservices receives CMO Leadership Awards for 2015

Paragon Bioservices, Inc., a leader in the manufacturing of biopharmaceuticals, has announced today that it has received the CMO Leadership Awards for 2015. Paragon is a leading contract manufacturing organization (CRO-CMO) whose customer base includes global pharmaceutical companies, biotechnology companies, NGOs and government agencies—including the Department of Defense, the National Cancer Institute and the National Institutes of Health (NIH). [More]
Alzheimer's Association announces new research grants to study potential drug therapies

Alzheimer's Association announces new research grants to study potential drug therapies

Many academic researchers and pharmaceutical companies have identified new Alzheimer's drug therapy candidates, but lack the funding to move them into human testing. At the same time, few funding sources support early-phase clinical drug trials. As a result, too many promising studies stall out early in the discovery process. [More]
Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

In a new research study, scientists from Vision Genomics, LLC, Insilico Medicine, Inc., and Howard University showed that Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) is comparable to normal aging with respect to cellular signaling pathways, and that HGPS truly recapitulates the normal aging process. [More]
Georgia Tech researchers unveil new version of genome annotation system

Georgia Tech researchers unveil new version of genome annotation system

Georgia Tech researchers, working with colleagues in the National Center for Biotechnology Information, have released a new version of a genome annotation system capable of analyzing more than 2,000 prokaryotic genomes per day, helping researchers accelerate prokaryotic genomics-based studies worldwide. [More]
Study shows how gut bacteria can affect normal brain activity

Study shows how gut bacteria can affect normal brain activity

The hundred trillion bacteria living in an adult human--mostly in the intestines, making up the gut microbiome--have a significant impact on behavior and brain health. The many ways gut bacteria can impact normal brain activity and development, affect sleep and stress responses, play a role in a variety of diseases, and be modified through diet for therapeutic use are described in a comprehensive Review article in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Colorectal cancer incidence increasing among young adults

Colorectal cancer incidence increasing among young adults

The incidence of colorectal cancer (CRC) among young adults ages 20-39 years has increased during the past 20-30 years, despite declining rates of CRC for the U.S. population overall. [More]

Future Science Group's first open access journal launched

Future Science Group has launched Future Science Open, the publisher's first fully open access journal. Each month, Future Science Open will publish research in all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are relevant to human health. [More]
Mount Sinai study measures ability of artificial pancreas in preventing hypoglycemia in T1D patients

Mount Sinai study measures ability of artificial pancreas in preventing hypoglycemia in T1D patients

A newly launched clinical research study at the Icahn School of Medicine at Mount Sinai is examining whether an artificial pancreas (AP) can prevent too low blood sugar levels or hypoglycemia in patients with type 1 diabetes (T1D) as they sleep. People fast as they sleep and nighttime hypoglycemia can cause seizures, and coma or death in rare cases, among the more than three million Americans with type 1 diabetes. [More]
Researchers find link between human population density and spread of Ebola virus in forested regions

Researchers find link between human population density and spread of Ebola virus in forested regions

Researchers at SUNY Downstate Medical Center have found an apparent link between human population density and vegetation cover in Africa and the spread of the Ebola virus from animal hosts to humans. [More]
Umbilical cord-derived stem cells from women with gestational diabetes show premature aging

Umbilical cord-derived stem cells from women with gestational diabetes show premature aging

Multipotent cells isolated from the human umbilical cord, called mesenchymal stromal cells (hUC-MSCs) have shown promise for use in cell therapy to treat a variety of human diseases. However, intriguing new evidence shows that hUC-MSCs isolated from women with gestational diabetes demonstrate premature aging, poorer cell growth, and altered metabolic function, as reported in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances. [More]
Daily use of Pycnogenol may help improve overall cognitive function

Daily use of Pycnogenol may help improve overall cognitive function

New research delivers exciting news for those seeking natural ways to boost memory and mental performance. A study recently published in the Journal of Neurosurgical Sciences shows daily use of Pycnogenol (pic-noj-en-all), a natural plant extract from French maritime pine tree bark, may help improve attention span, memory, decision-making – including executive-level performance – and overall cognitive function. [More]
Researchers invent new imaging system to help detect malignant tissue during surgery

Researchers invent new imaging system to help detect malignant tissue during surgery

With the goal of making it easier for surgeons to detect malignant tissue during surgery and hopefully reduce the rate of cancer recurrence, scientists have invented a new imaging system that causes tumors to "light up" when a hand-held laser is directed at them. [More]
Commercial space transportation industrys need to define medical care standards

Commercial space transportation industrys need to define medical care standards

The commercial aviation industry has medical care standards, as does NASA for traditional space missions, and the emerging commercial space transportation industry will need to define medical care practices as well. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
New article discusses role of cytokines in breast cancer development, progression

New article discusses role of cytokines in breast cancer development, progression

Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such as interleukin and transforming growth factor-β play in breast cancer initiation, protection, and metastasis. [More]
Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers. [More]
Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. [More]
Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

The study carried out by researchers from the Centre for Plant Biotechnology and Genomics along with the Allergy Department of the Hospital Infantil Universitario Niño Jesús of Madrid have shown that, most of the children that received this new oral immunotherapy treatment were able to eat 100 grams of wheat bread without side effects. This result has overcome the risk of accidental ingestion by patients with this allergy. This research could be the basis for large clinical trials with more patients with the aim of assessing the therapeutic benefit of this new approach. [More]